Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 49

1.

Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.

Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, Dietrich D, Biesmans B, Bodoky G, Barone C, Aranda E, Nordlinger B, Cisar L, Labianca R, Cunningham D, Van Cutsem E, Bosman F.

J Clin Oncol. 2010 Jan 20;28(3):466-74. doi: 10.1200/JCO.2009.23.3452. Epub 2009 Dec 14.

2.

PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer.

Ogino S, Nosho K, Kirkner GJ, Shima K, Irahara N, Kure S, Chan AT, Engelman JA, Kraft P, Cantley LC, Giovannucci EL, Fuchs CS.

J Clin Oncol. 2009 Mar 20;27(9):1477-84. doi: 10.1200/JCO.2008.18.6544. Epub 2009 Feb 23.

3.

JC virus T-antigen in colorectal cancer is associated with p53 expression and chromosomal instability, independent of CpG island methylator phenotype.

Nosho K, Shima K, Kure S, Irahara N, Baba Y, Chen L, Kirkner GJ, Fuchs CS, Ogino S.

Neoplasia. 2009 Jan;11(1):87-95.

4.

A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer.

Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Chan AT, Schernhammer ES, Giovannucci EL, Fuchs CS.

J Natl Cancer Inst. 2008 Dec 3;100(23):1734-8. doi: 10.1093/jnci/djn359. Epub 2008 Nov 25.

5.

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A.

J Clin Oncol. 2008 Dec 10;26(35):5705-12. doi: 10.1200/JCO.2008.18.0786. Epub 2008 Nov 10.

6.

Cohort study of fatty acid synthase expression and patient survival in colon cancer.

Ogino S, Nosho K, Meyerhardt JA, Kirkner GJ, Chan AT, Kawasaki T, Giovannucci EL, Loda M, Fuchs CS.

J Clin Oncol. 2008 Dec 10;26(35):5713-20. doi: 10.1200/JCO.2008.18.2675. Epub 2008 Oct 27.

7.

CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer.

Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Meyerhardt JA, Loda M, Giovannucci EL, Fuchs CS.

Gut. 2009 Jan;58(1):90-6. doi: 10.1136/gut.2008.155473. Epub 2008 Oct 2.

8.

Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials.

Mitry E, Fields AL, Bleiberg H, Labianca R, Portier G, Tu D, Nitti D, Torri V, Elias D, O'Callaghan C, Langer B, Martignoni G, Bouché O, Lazorthes F, Van Cutsem E, Bedenne L, Moore MJ, Rougier P.

J Clin Oncol. 2008 Oct 20;26(30):4906-11. doi: 10.1200/JCO.2008.17.3781. Epub 2008 Sep 15.

9.

Genomic and epigenetic instability in colorectal cancer pathogenesis.

Grady WM, Carethers JM.

Gastroenterology. 2008 Oct;135(4):1079-99. doi: 10.1053/j.gastro.2008.07.076. Epub 2008 Sep 4. Review.

10.

Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer.

Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse M, Mitchell E, Miller MC, Doyle GV, Tissing H, Terstappen LW, Meropol NJ.

J Clin Oncol. 2008 Jul 1;26(19):3213-21. doi: 10.1200/JCO.2007.15.8923. Erratum in: J Clin Oncol. 2009 Apr 10;27(11):1923.

11.

PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations.

Nosho K, Kawasaki T, Ohnishi M, Suemoto Y, Kirkner GJ, Zepf D, Yan L, Longtine JA, Fuchs CS, Ogino S.

Neoplasia. 2008 Jun;10(6):534-41.

12.

Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial.

Braun MS, Richman SD, Quirke P, Daly C, Adlard JW, Elliott F, Barrett JH, Selby P, Meade AM, Stephens RJ, Parmar MK, Seymour MT.

J Clin Oncol. 2008 Jun 1;26(16):2690-8. doi: 10.1200/JCO.2007.15.5580. Erratum in: J Clin Oncol. 2008 Sep 10;26(26):4363.

13.

LINE-1 hypomethylation is inversely associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer.

Ogino S, Kawasaki T, Nosho K, Ohnishi M, Suemoto Y, Kirkner GJ, Fuchs CS.

Int J Cancer. 2008 Jun 15;122(12):2767-73. doi: 10.1002/ijc.23470.

14.

Individualized prediction of colon cancer recurrence using a nomogram.

Weiser MR, Landmann RG, Kattan MW, Gonen M, Shia J, Chou J, Paty PB, Guillem JG, Temple LK, Schrag D, Saltz LB, Wong WD.

J Clin Oncol. 2008 Jan 20;26(3):380-5. doi: 10.1200/JCO.2007.14.1291.

15.

Molecular classification and correlates in colorectal cancer.

Ogino S, Goel A.

J Mol Diagn. 2008 Jan;10(1):13-27. doi: 10.2353/jmoldx.2008.070082. Epub 2007 Dec 28. Review.

16.

The Cables gene on chromosome 18q is silenced by promoter hypermethylation and allelic loss in human colorectal cancer.

Park DY, Sakamoto H, Kirley SD, Ogino S, Kawasaki T, Kwon E, Mino-Kenudson M, Lauwers GY, Chung DC, Rueda BR, Zukerberg LR.

Am J Pathol. 2007 Nov;171(5):1509-19.

17.

Correlation of beta-catenin localization with cyclooxygenase-2 expression and CpG island methylator phenotype (CIMP) in colorectal cancer.

Kawasaki T, Nosho K, Ohnishi M, Suemoto Y, Kirkner GJ, Dehari R, Meyerhardt JA, Fuchs CS, Ogino S.

Neoplasia. 2007 Jul;9(7):569-77.

18.

Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample.

Ogino S, Kawasaki T, Kirkner GJ, Kraft P, Loda M, Fuchs CS.

J Mol Diagn. 2007 Jul;9(3):305-14.

19.

Aspirin and the risk of colorectal cancer in relation to the expression of COX-2.

Chan AT, Ogino S, Fuchs CS.

N Engl J Med. 2007 May 24;356(21):2131-42.

20.
Items per page

Supplemental Content

Write to the Help Desk